Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 1(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01894412Phase 1Completed

Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers

Role: lead

NCT01270997Phase 3Completed

Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients

Role: lead

NCT01044836Phase 1Completed

Safety and Pharmacokinetic Characteristics of HD203 in Healthy Male Volunteers

Role: lead

NCT01431404Phase 1Completed

Safety and Pharmacokinetic Characteristics of HD203 Liq. in Healthy Subjects

Role: lead

All 4 trials loaded